Extrait

To assess the safety of the HPV-16/18 L1 VLP AS04 vaccine throughout the study period.

Critère d'inclusion

• Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18 ,In addition, Cervarix has shown efficacy against persistent infection caused by oncogenic HPV types other than HPV-16 and HPV-18

Liens

• ictrp
• euctr